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Background: Mutations in parkin are estimated to ac-
count for as much as 50% of familial Parkinson disease
(PD) and 18% of sporadic PD. Single heterozygous mu-
tations in parkin in both familial and sporadic cases may
also increase susceptibility to PD. To our knowledge, all
previous studies have been restricted to PD cases; this is
the first study to systematically screen the parkin coding
regions and exon deletions and duplications in controls.
Objective: To determine the frequency and spectrum
of parkin variants in early-onset PD cases (aged!50 years)
and controls participating in a familial aggregation study.
Patients andMethods:We sequenced the parkin gene
in 101 cases and 105 controls. All cases and controls were
also screened for exon deletions and duplications by semi-
quantitative multiplex polymerase chain reaction.
Results: Thirteen (12.9% [95% confidence interval,
7%-21%]) of the 101 cases had a previously described
parkinmutation: 1 was homozygous, 11 were heterozy-
gous, and 1 was a compound heterozygote. The muta-
tions Arg42Pro (exon 2) and Arg275Trp (exon 7) were
recurrent. The previously reported synonymous substi-
tution Leu261Leu (c.884A"G)was identified in 4 (3.9%)
of 101 cases and 2 (2%) of 105 controls (P=.44). Ex-
cluding the synonymous substitution Leu261Leu (het-
erozygotes), 10 (9.9% [95% confidence interval, 4.6%-
17.5%]) carried mutations.
Conclusions: The frequency of mutations among cases
that were not selected based on family history of PD is
similar to what has previously been reported in spo-
radic PD. The similar frequency of Leu261Leu in cases
and controls suggests it is a normal variant rather than a
disease-associated mutation. We confirmed that hetero-
zygous parkinmutations may increase susceptibility for
early-onset PD.
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M UTATIONS IN 4 GENES,α-synuclein(PARK1),1,2parkin (PARK2),3 DJ-1(PARK7),4-6 and PINK1(PARK6),7-11 are associ-
ated with early-onset Parkinson disease
(EOPD). Parkinmutations account for the
majority of familial and sporadic EOPD
cases with a known genetic association.3,12
In PD cases with age at onset (AAO) of 45
years or younger, the frequency of parkin
mutations is estimated at 49% in caseswith
a family history of PD13 and 15% in cases
without a family history of PD.14 In the only
community-based study, the frequency of
mutations was 9% in 111 cases with AAO
of 50 years or younger.15
In both familial and sporadic cases,
homozygous, compound heterozygous,
and single heterozygous mutations in
parkin have been described. Several stud-
ies indicate that heterozygous mutations
may increase susceptibility to PD,3,16-19
although this is controversial. The carrier
(heterozygous) frequency of parkin
alleles in the normal population is
unknown. Previous studies have only
assessed the frequency of specific parkin
mutations and/or variants that were
identified in PD cases and have not sys-
tematically screened the parkin gene for
mutations in normal controls.3,20
We have screened participants in the
Genetic Epidemiology of PD Study
(GEPD) for variants in DJ-121 and gluco-
cerebrosidase.22 In the present study, to
identify variants in the parkin gene, cod-
ing exons were sequenced completely in
206 subjects, including 101 EOPD cases
and 105 controls from GEPD. All sub-
jects (cases and controls) were also
screened for exon deletions and duplica-
tions by semiquantitative multiplex poly-
merase chain reaction (PCR).
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Caseswere recruited based onAAOofmotor signs of 50 years or
younger (EOPD), regardless of family history of PD in a first-
degree relative. All cases were seen at the Center for Parkinson’s
Disease and Other Movement Disorders at Columbia Univer-
sity, and EOPD cases were oversampled.23 Duration of PD was
calculated as the years frommotor onset to enrollment inGEPD.
We have previously shown that reliability of reporting the AAO
ofmotor signs of PDwas excellent.23 All parkin coding exonswere
sequenced and analysis of exon deletions and duplications were
completed in 101of 256EOPDcases fromGEPD23 onwhomdata
were complete at the time of the analysis. The current study in-
cludes 21 of 33 cases previously screened for parkin variants.24
Analysis was performed without knowledge of these results.
Controls
Onehundred five of 412 controls fromGEPDonwhomdatawere
complete were randomly chosen for sequencing of parkin exons
and analysis of exon deletions and duplications by semiquanti-
tativemultiplex PCR. For PD cases recruited from theCenter for
Parkinson’sDisease andOtherMovementDisorders, controlswere
recruited by random-digit dialing and were frequency matched
based on key demographic variables.23 For cases who were resi-
dents of Washington Heights, Manhattan, NY, and 65 years or
older, controls were recruited from a 50% sample of names and
addresses of Medicare recipients provided by Health Care Fi-
nance Association. For 18 cases younger than 65 years, controls
were recruited from the Northern Manhattan Stroke Study in
Washington Heights.25 For the analysis of variants in exon 7, in-
cluding the synonymous substitution Leu261Leu, an additional
82 Hispanic controls from the 50% Medicare sample were in-
cluded to enrich the number of Hispanic controls.
All PD case and control probands underwent an evaluation
that included a medical history and Unified Parkinson’s Dis-
easeRating Scale26 and videotape assessment. ThemodifiedMini-
Mental State Examination was administered to all probands in
either English or Spanish.27 A valid, reliable, structured family
history of PD questionnaire (Family History Information) was
administered in English or Spanish to all PD cases and con-
trols, either in person or over the telephone, for ascertainment
of PD and other neurologic disease in first-degree relatives.28
The institutional review board at the College of Physicians and
Surgeons, Columbia University, approved this study. In-
formed consent was obtained from all study participants.
MOLECULAR GENETIC ANALYSIS
DNA was isolated from whole blood using standard tech-
niques. All blood and genomic DNA samples were coded on
receipt to ensure patient confidentiality. Polymerase chain re-
action amplification of parkin exons 1 to 12 was performed in
cases and controls. The primers used for PCR amplification of
parkin exons and intronic and exonic boundaries and sequenc-
ing have been described previously.29,30 Cycle sequencing was
performed on the purified PCR product as per the manufac-
turer’s instructions (BigDye; Applied Biosystems, Foster City,
Calif ). Products were analyzed on an ABI3700 genetic ana-
lyzer (Applied Biosystems). Chromatograms were viewed us-
ing Sequencher (Gene Codes Corporation, Ann Arbor, Mich)
and sequence variants determined. All sequence variants iden-
tified in cases and controls were confirmed by analysis in a sepa-
rate PCR followed by bidirectional sequencing. Sequence vari-
ants were classified as polymorphic if their frequency was 1%
or greater in ethnically matched controls. These analyses were
performed without knowledge of case-control status.
To identify genomic deletions and exon rearrangements in
parkin, semiquantitative multiplex PCRwas performed as pre-
viously described.31 Briefly,Hex-tagged fluorescent-labeled prim-
ers for parkin exons were optimised in pooled sets of 4 primer
pairs for multiplexing along with an internal control (328-bp
PCR product of an unlinked gene transthyretin on chromo-
some 18). The PCR fragments were analyzed on an ABI3700
genetic analyzer. Electropherograms were viewed and prod-
uct size and peak heights calculated using Genescan 3.1 and
Genotyper software (Applied Biosystems).
DATA ANALYSIS
Baseline characteristics at the time of enrollmentwere compared
using the t test for continuous variables and the #2 test or Fisher
exact test for categorical variables. First, we compared the demo-
graphic characteristics of the subjects who were included in the
analysisofparkinvariantswith thoseof thesubjectswhowerenot.
Second,wecomparedthedemographiccharacteristicsofcasesand
controls who were analyzed for parkin. Third, we compared the
demographic and clinical characteristics of cases with and with-
outmutations in theparkingene.TheWilcoxonranksumtestwas
used to compare the total modified Mini-Mental State Examina-
tionscore inPDcaseswithandwithoutparkinmutationsbecause
of the inadequacy of normality assumption of the distribution.
In a separate analysis including an additional 82Hispanic con-
trols, we compared the frequency of Leu261Leu in cases and con-
trols and performed a stratified analysis by ethnic group to de-




OF THE CASE-CONTROL COHORT
At the time of this study, 668 subjects including 256EOPD
cases and 412 controls had been recruited into GEPD. All
parkin coding exonswere sequenced and analyzed for exon
deletions andduplications in a subset of 206 (101PDcases
with AAO!50 years and 105 controls). Demographic and
clinical characteristics of the 206 cases and controls are pre-
sented in Table 1. The mean (SD) AAO of 101 cases was
41.1 (7.2) years, disease durationwas 11.7 (8.0) years, and
totalmotor score (Unified Parkinson’sDiseaseRating Scale
Part III) was 21.0 (13.00). Compared with the subjects in
whom parkin was not sequenced (n=462), the 206 cases
and controls were younger (56.9 vs 63.2 years; P$.001),
had completedmore years of education (15.6 vs 14.5 years;
P$.001), andweremore likely tobewhite (89.3%vs66.8%;
P$.03).Cases inwhomtheparkingenewas sequenced and
analyzed for exon deletions and duplications (n=101) did
not differ significantly from cases who were not analyzed
(n=155) in AAO of PD, age at evaluation, years of educa-
tion, ethnicity, sex, or family history of PD. Those cases in
whom the gene was analyzed had longer duration of PD
(11.9vs10.0years;P=.05); however,HoehnandYahr score
and total motor score on the Unified Parkinson’s Disease
Rating Scale Part III were similar to nonsequenced cases.
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FREQUENCY OF PARKIN MUTATIONS
IN CASES AND CONTROLS
Thirteen (12.9%) (95% confidence interval [CI], 7%-
21%) of the 101 cases had a previously described parkin
mutation; 1was homozygous, 11were heterozygous, and
1 was a compound heterozygote (Table 2). Five differ-
ent point mutations and 3 different exon rearrangements
were identified (Table 2). Pointmutations included 3mis-
sensemutations, 1 synonymous substitution, and 1 splice
mutation. Exon deletions were found in 3 different exons
(exons 3, 4, and 5). Fifty-four percent (7/13) of the vari-
ants identified in caseswere found in exons encoding func-
tional domains including the ubiquitin domain (exons 2
and 3) and RING1 domain (exon 7). The mutations
Arg275Trp, Arg42Pro, and the synonymous substitution
Leu261Leu were recurrent; 2 cases carried Arg275Trp, 2
carried Arg42Pro, and 4, including 1 compound hetero-
zygote, carried Leu261Leu (3 Hispanic subjects, 1 white
non-Hispanic subject). The synonymous substitution
Leu261Leuwas identified in 2% (2/105) of controls (1His-
panic subject and 1 African American subject). To our
knowledge, all previously published studies have evalu-
ated the Leu261Leu allele frequency only in white non-
Hispanic control subjects. Because we identified the syn-
onymous substitution in Hispanic and white non-
Hispanic subjects and our pool of Hispanic controls was
limited (n=4), we added 82 Hispanic controls from the
50% Health Care Finance Association sample to the ex-
isting control group (n=105). We found that 13% (11/
86) of Hispanic controls carried the synonymous substi-
tution Leu261Leu (Table 3). The allele frequency was
higher in Hispanic cases and controls combined, 14.4%
(14/97), compared with all other ethnicities, including
white non-Hispanic, African American, and Asian cases
and controls combined (1.1% [2/191]) (P$.001).
FREQUENCY OF PARKIN POLYMORPHISMS
The previously reported parkin polymorphisms, IVS3-
20C"T, IVS2%25T"C, IVS7-35A"G, Ser167Asn,
Asp394Asn, and Val380Leu, were observed at a similar
frequency in cases and controls and were not signifi-
cantly associated with PD (data not shown).
CLINICAL CHARACTERISTICS OF CASES
WITH AND WITHOUT PARKIN MUTATIONS
Demographic and clinical characteristics of 91 caseswith-
out parkinmutations and 10 cases (excluding 3 caseswith









Male, No. (%) 119 (57.8) 60 (59.4) 59 (56.2) .64
Age, y, mean (SD) 56.9 (10.9) 53.0 (9.8) 60.6 (10.6) .001
Ethnicity, No. (%)
White 184 (89.3) 87 (86.1) 97 (92.4) .04*
African American 3 (1.5) 0 3 (2.9)
Hispanic 15 (7.3) 11 (10.9) 4 (3.8)
Other 4 (1.9) 3 (3.0) 1 (1.0)
Education, y, mean (SD) 15.6 (3.0) 15.7 (3.1) 15.5 (2.9) .61
With parkin variants, No. (%) 11 (5.34) 11 (10.9) 0 $.001
With family history of PD, No. (%)† 19 (9.4) 13 (13.4) 6 (5.7) .06
Abbreviation: PD, Parkinson disease.
*Fisher exact test.
†Family history was available for 202 subjects (97 cases and 105 controls).
Table 2. Parkin Mutations Identified in Cases
Patient Exon Mutation Zygosity Ethnicity Age at Onset, y
1 1 c.81G"T and Leu261Leu Compound heterozygous Hispanic 28
2 2 Arg42Pro Heterozygous White non-Hispanic 44
3 2 Arg42Pro Heterozygous White non-Hispanic 44
4 3 Exon 3 40-bp deletion (c.438-477) Homozygous White non-Hispanic 38
5 3, 4 Exons 3 and 4 deletion Heterozygous Hispanic 16
6 5 Met192Leu Heterozygous Hispanic 36
7 5 Exon 5 deletion Heterozygous White non-Hispanic 48
8 5 Exon 5 deletion Heterozygous White non-Hispanic 50
9 7 Leu261Leu Heterozygous White non-Hispanic 41
10 7 Leu261Leu Heterozygous Hispanic 41
11 7 Leu261Leu Heterozygous Hispanic 47
12 7 Arg275Trp Heterozygous White non-Hispanic 47
13 7 Arg275Trp Heterozygous Other 24
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the synonymous substitution Leu261Leu) with muta-
tions are presented in Table 4. Information on history
of PD in first-degree relatives was available for 97 of 101
cases and 9 of 11 parkin mutation carriers. The fre-
quency of parkin mutations was 15.4% (2/13) in cases
with a family history of PD in a first-degree relative, com-
pared with 8.3% (7/84) in those without a family his-
tory of PD (P=.35). The 2 cases with parkin mutations
who reported a family history of PD in a first-degree rela-
tive had AAOs of 32 and 38 years, respectively. One of
the probands, the only homozygote (AAO, 38 years), had
2 siblings with PD (AAOs, 26 and 30 years). The fre-
quency of parkinmutations (n=10)was 50% (1/2) in cases
with AAO of 20 years and younger, 33% (2/6) in cases
with AAO of 21 to 30 years, 9% (3/33) in cases with AAO
of 31 to 40 years, and 7% (4/60) in cases with AAO of 41
to 50 years.Noncarriers and carriers did not differ in terms
of first symptom reported (rest tremor, bradykinesia, ri-
gidity, or gait impairment) nor did they differ in terms
of current use of levodopa/carbidopa or dopamine ago-
nists. None of the cases reported hallucinations or cog-
nitive impairment precedingmotor signs. Cases were not
specifically queried about sleep benefit or sensitivity to
levodopa in GEPD.
COMMENT
Theprevalence of parkinmutations in 101 caseswithAAO
younger than 50 years was 9.9% (95% CI, 4.9%-17.5%)
(excluding 3 heterozygous cases with the synonymous
substitution Leu261Leu) and 8.3% (95%CI, 3.4%- 16.4%)
among those cases who did not report a family history
of PD in a first-degree relative, which is within the range
(9%-18%) reported in other series comprising primarily
sporadic cases.14,15,32 The frequency of parkinmutations
in cases with AAO younger than 45 years in our study
was 11.1% (95% CI, 4.6%-21.6%), which is very similar
to the 15% frequency reported by Periquet et al14 in pa-
tients with isolated early-onset parkinsonism (AAO,$45
years). Phenotypic differences were not observed be-
tween cases with and without parkin mutations in this
study; however, detailed psychiatric and cognitive as-
sessments were not performed. The synonymous sub-
stitution Leu261Leu (c.884A"G), which has been pre-
viously described as a mutation,24,33 was identified with
similar frequency in cases and controls, suggesting that
it is a common variant rather than a disease-associated
mutation. The frequency of this variant appeared to be
higher in Hispanic subjects than in non-Hispanic sub-
jects. Our current sample size was insufficient to assess
definitively the possibility that the synonymous substi-
tution Leu261Leu is a susceptibility allele, and func-
tional data are not available to determine pathogenicity.
Based on the allele frequencies we observed in subjects
of Hispanic ethnicity, a sample size of 934 (467 cases and
467 controls) would have been required to detect a sta-
tistically significant difference (80% power, &=.05).
Toourknowledge, this is the first study todescribe com-
plete sequencingofparkincodingexonsandanalysisof exon
deletions andduplicationsby semiquantitativePCR incases
and controls. Several studies have reported heterozygous
parkin mutations in both EOPD and late-onset
PD.18,20,24,29,32-40 Currently, the identification of heterozy-
gousmutations in patients with PD is controversial, and it
is unknown whether heterozygous mutations alone are
pathogenic or whether additional mutations have been
missed in screening the parkin gene in these studies. Our
current study helps clarify this issue by screening controls
and finding that heterozygous mutations are absent. The
Table 3. Leu261Leu Synonymous Substitution Status
and Case-Control Status Stratified by Ethnicity





Sample Size Total P Value
White
Case 1 86 87
.47Control 0 97 97
Total 1 183 184
Hispanic
Case 3 8 11
.19Control 11 75 86
Total 14 83 97
Other
Case 0 3 3
".99Control 1 3 4
Total 1 6 7
Total
Case 4 97 101
.44Control 12 175 187
Total 16 272 288
Table 4. Cases With and Without Parkin Mutations







Current age, y, mean (SD) 53.8 (9.7) 45.8 (8.0) .01
Age at onset, y, mean (SD) 41.6 (6.5) 36.3 (11.3) .18
Male, No. (%) 57 (62.6) 3 (30.0) .08
Ethnicity, No. (%) .05
White 81 (89.0) 6 (60.0)
Hispanic 8 (8.8) 3 (30.0)
Other 2 (2.2) 1 (10.0)
Education, y, mean (SD) 15.9 (3.1) 13.6 (2.6) .02
Duration of PD, y, mean (SD) 12.2 (8.2) 9.5 (6.4) .24
UPDRS Part III26 total
motor score, mean (SD)
21.4 (13.4) 17.5 (9.4) .26
mMMSE27 total score (SD) 53.7 (4.5) 53.2 (5.4) .72
Family history of PD
in first-degree relative, %
(No./Total No.)
12.5 (11/88) 22.2 (2/9) .35
Bradykinesia, % 78.0 90.0 .68
Rest tremor, % 77.8 70.0 .69
Rigidity, % 98.9 100.0 ".99
Postural instability, % 50.6 20.0 .09
Asymmetry, % 83.2 100.0 .35
Improvement with levodopa, % 98.5 100.0 ".99
Taking levodopa, % 76.4 66.7 .68
Presence of dyskinesias, % 47.1 50.0 ".99
Hoehn and Yahr score, mean (SD) 2.3 (0.97) 2.1 (0.17) .08
Abbreviations: mMMSE, modified Mini-Mental State Examination; PD,
Parkinson disease; UPDRS, Unified Parkinson’s Disease Rating Scale.
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absence of control subjects carryingparkinmutations sug-
gests that heterozygousparkinmutationsmay increase sus-
ceptibility for EOPD. There are few functional studies to
support the hypothesis that parkin heterozygous muta-
tions are pathogenic. However, 1 study41 has demon-
strated that 2RING finger1mutations (R256CandR275W)
are dominant gain-of-function mutations, which is con-
sistent with the identification of heterozygous mutations
in several studies and supports the hypothesis that parkin
heterozygous mutations are pathogenic. Other strengths
of this study include that all cases and controls fromGEPD
were administered reliable, structured neurologic exami-
nations and family history of PD interviews. The identifi-
cation of possible ethnic differences in allele frequencies
for theLeu261Leuvarianthighlights the importanceofwell-
characterized multiethnic samples in determining disease
susceptibility alleles and in diagnostic screening.
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